Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Follow-Up Questions
Who is the CEO of Pelthos Therapeutics Inc?
Mr. Scott Plesha is the President of Pelthos Therapeutics Inc, joining the firm since 2025.
What is the price performance of PTHS stock?
The current price of PTHS is $29, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Pelthos Therapeutics Inc?
Pelthos Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Pelthos Therapeutics Inc market cap?
Pelthos Therapeutics Inc's current market cap is $89.0M
Is Pelthos Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Pelthos Therapeutics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
